Crinetics Pharmaceuticals (CRNX) Equity Ratio (2017 - 2026)

Crinetics Pharmaceuticals' Equity Ratio history runs 10 years deep, the most recent figure standing at 0.91 for Q1 2026.

• In Q1 2026, Equity Ratio fell 0.79% year-over-year to 0.91; the TTM figure through Mar 2026 stood at 0.91 (down 0.79% YoY), while the FY2025 annual figure was 0.88, down 4.61% from the prior year.
• Equity Ratio was 0.91 for Q1 2026 at Crinetics Pharmaceuticals, up from 0.88 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.92 in Q4 2024 to a low of 0.85 in Q4 2023.
• Historically, Equity Ratio has averaged 0.89 across 5 years, with a median of 0.9 in 2025.
• The sharpest annual moves came in 2023 and 2024: Equity Ratio declined 6.48% in 2023, then increased 8.83% in 2024.
• A 5-year view of Equity Ratio shows it stood at 0.9 in 2022, then dropped by 5.53% to 0.85 in 2023, then gained by 8.83% to 0.92 in 2024, then dropped by 4.61% to 0.88 in 2025, then gained by 3.75% to 0.91 in 2026.
• The last three Equity Ratio figures came in at 0.91 (Q1 2026), 0.88 (Q4 2025), and 0.9 (Q3 2025), per Business Quant data.